Differential distribution of striatal [123I]β-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography

European Journal of Nuclear Medicine

Volumn 25, Issue 9, 1998, Pages 1270-1276

  Messa, C ^a,b   Volonte M A ^a   Fazio, F ^a   Zito, F ^a   Carpinelli, A ^a   D'Amico, A ^a   Rizzo, G ^a   Moresco, R M ^a   Paulesu, E ^a   Franceschi, M ^a   Lucignani, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Extrapyramidal disorders; Iodine 123 CIT; Single photon emission tomography

Indexed keywords

2 BETA CARBOXYMETHOXY 3 BETA (4 IODOPHENYL)TROPANE; IODINE 123; TRACER; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL GANGLION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; BASAL GANGLIA; COCAINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PARKINSON DISEASE; SUPRANUCLEAR PALSY, PROGRESSIVE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 15644363342     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050295     Document Type: Article

References (31)

1. Maher ER, Lees AJ. The clinical features and natural history of Steel-Richardson-Olszewski syndrome (progressive supra-nuclear palsy). Neurology 1986; 36: 1005-1008.
2. Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steel-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 60: 615-620
3. Stern MB, Braffman BH, Skolnick BE, Hurtig HI. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology 1989; 39: 1524-1526.
4. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-555.
5. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RSJ. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 1990; 113: 1539-1552.
6. Brooks DJ. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology 1993; 43: S6-S16.
7. 18F-dopa uptake: difference in Parkinson's disease and atypical Parkinsonism. J Neurol Neurosurg Psychiatry 1991; 54: 898-904.
8. 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994; 57: 278-284.
9. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden D, Frackowiak RSJ. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990, 47: 1290-1298.
10. 123I]β-CIT. Eur J Pharmacol 1991; 200: 369-370.
11. 121I]β-CIT in healthy human subjects. J Nucl Med 1994; 35: 764-770.
12. 123I]β-CIT binding to dopamine transporters in heally human subjects. J Cereb Blood Flow Metab 1994; 14: 982-994.
13. Kuikka JT, Tiihonen J, Bergstrom KA, et al. Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med 1995; 22: 346-350.
14. Innis RB, Seibyl JP, Scanley BE, Laurelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, Gao Y, Neumeyer JL, Charney DS, Hoffer PB, Marek KL. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acatl Sci USA 1993; 90: 11965-11969.
15. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single photon emission computed tomography [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
16. Rinne JO, Kuikka JT, Bergstrom KA, Rinne UK: Striatal dopamine transporters in different disability stages of Parkinson's disease studied with [123I]β-CIT SPECT. Parkinsonism and Related Disorders 1995; 47-51.
17. Asenbaum S, Bruke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease. J Nucl Med 1997; 38: 1-6.
18. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237.
19. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992; 32: S125-S127.
20. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International workshop. Neurology 1996; 47: 1-9.
21. Hoen MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 6: 253-259.
22. Fahn S, Elton R and the members of UPDRS development committee: Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Clane DB, Goldstein M, eds. Recent developments in Parkinson's disease, vol 2. Florham Park, N.J.: Macmillian Health Care Information; 1987; 153-163, 293-304.
23. Neumeyer JL, Wang S, Milius RA, et al. Iodine-123-2-β-carboxymethoxy-3-β-(4-iodophenyl)tropane (βCIT): high affinity SPECT radiotracer of monoamine reuptake sites in brain. J Med Chem 1991; 34: 3144-3146.
24. 123I]β-CIT, a tracer for dopamine and serotonin reuptake sites, preparation and preliminary SPET studies in humans. J Nucl Biol Med 1994; 38: 128-131.
25. Genna S, Smith AP. The development of ASPECT, an annular single crystal brain camera for high efficiency SPECT. IEEE Trans Nucl Sci 1988; NS-35: 654-658.
26. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978; NS-25: 638-643.
27. Arun KS, Huang TS, Blostein SD. Least-square fitting of two 3D point sets. IEEE Trans PAMI 1987; 9: 698-700.
28. Staffen W. Hondld N, Trinka E, Zenzmaier R, Ladurner G. SPET investigations in extrapyramidal disease using specific ligands. Nucl Med Commun 1997; 18: 159-163.
29. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in Parkinson's disease, striato-nigral degeneration, and progressive supranuclear palsy measured with [C-11]raclopride and PET. Ann Neurol 1992; 31: 184-192.
30. 123IM-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 1993; 43: S17-S20.
31. Tissingh G, Booij J, Winogrodzka A, et al. IBZM-and CIT-SPECT of the dopaminergic system in parkinsonism. J Neural Transm 1997; 50: 31-37.